Pegcetacoplan not checked
Apellis Pharmaceuticals, Inc. · APL-2
FollowEvery change as it happens, and a Monday email
Trials
5 active
21 in total · 8 in the EU
What this is
- How it works
- Blocks part of the complement system, a branch of the immune system that can attack the body's own cells.Complement Inhibitor FDA class
- How it’s given
- “Solution for infusion for subcutaneous use according to drug use in the real world.”In the company’s words, NCT07746895 on ClinicalTrials.gov
- Tested for
- Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN) (2 trials), C3 Glomerulopathy (C3G), C3G, IC-MPGN, C3 Glomerulopathy, C3 Glomerulonephritis, Complement 3 Glomerulopathy, Complement 3 Glomerulopathy (C3G) and 10 more
- Main trialPhase 4
- “The purpose of this study is to evaluate the effectiveness and safety of Pegcetacoplan in patients with C3G and primary IC-MPGN in the real-world setting. This study will also assess biomarkers not routinely measured in clinical practice. Results will support the long-term evaluation of the benefit-risk profile of pegcetacoplan in a broad patient population, informing clinical decision-making.”In the company’s words, NCT07746895 on ClinicalTrials.gov
- Other names
- APL-2
- Given with
- Soliris (Alexion Pharm)Other companies’ drugs in its trials
Other drugs for Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN)
Coming up5
- Jul 2027Phase 3 trial completes · ClinicalTrials.gov
- Dec 2028Phase 2 trial completes · ClinicalTrials.gov
- Oct 2029Phase 2/3 trial completes · ClinicalTrials.gov
- 17 Jan 2031Phase 3 trial completes · ClinicalTrials.gov
- 31 Dec 2031Phase 4 trial completes · ClinicalTrials.gov
Changes1
Last 90 days- 9 NovStatus changed: Not yet recruiting to Recruiting · ClinicalTrials.gov NCT07898774
Trials21
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 4Recruiting | 31 Dec 2031 | Real-World Effectiveness and Safety of Pegcetacoplan in Patients With C3G or IC-MPG: A Multi-Country Study | |
| Phase 3Active, not recruiting | Jul 2027 | An Open-Label, Nonrandomized, Multicenter Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan in Participants With C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis | |
| Phase 3Recruiting | 17 Jan 2031 | A Study to Assess the Efficacy and Safety of Pegcetacoplan for the Prevention of Recurrent C3G or Primary IC-MPGN in Kidney Transplant Recipients | |
| Phase 2/3Recruiting | Oct 2029 | A Sequential Phase 2/3 Study of APL2 in Patients With Focal Segmental Glomerulosclerosis | |
| Phase 2Recruiting | Dec 2028 | A Study of Pegcetacoplan in Pediatric Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) | |
| Phase 3Completed | 14 Nov 2019 | Study to Evaluate the Efficacy and Safety of APL-2 in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) | |
| Phase 3Completed | 21 Jun 2021 | Study to Compare the Efficacy and Safety of Intravitreal APL-2 Therapy With Sham Injections in Patients With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration | |
| Phase 3Completed | 23 Jun 2021 | A Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Patients With PNH | |
| Phase 3Completed | 28 Jun 2021 | A Study to Compare the Efficacy and Safety of Intravitreal APL-2 Therapy With Sham Injections in Patients With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration | |
| Phase 3Completed | 26 Jun 2024 | Phase III Study Assessing the Efficacy and Safety of Pegcetacoplan in Patients With C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis | |
| Phase 3Completed | 4 Sep 2025 | Pegcetacoplan Long Term Safety and Efficacy Extension Study | |
| Phase 3Completed | 5 Sep 2025 | An Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan (APL-2) in Subjects With Geographic Atrophy Secondary to AMD | |
| Phase 3Completed | 12 Dec 2025 | Study to Evaluate a Pegcetacoplan (Syfovre®) Prefilled Syringe | |
| Phase 3Withdrawn | Jun 2029 | Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Adults at High Risk of Delayed Graft Function (DGF) Following Kidney Allograft Transplantation | |
| Phase 2Completed | 16 Apr 2020 | Phase II Study Assessing Safety and Efficacy of APL-2 in Glomerulopathies | |
| Phase 2Completed | 12 Sep 2022 | Study to Assess the Safety, Tolerability, Efficacy and PK of APL-2 in Patients With Warm Type Autoimmune Hemolytic Anemia (wAIHA) or Cold Agglutinin Disease (CAD) | |
| Phase 2Completed | 27 Feb 2023 | Study Assessing the Safety and Efficacy of Pegcetacoplan in Post-Transplant Recurrence of C3G or IC-MPGN | |
| Phase 2Terminated | 31 Mar 2023 | MERIDIAN: A Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Adults With Amyotrophic Lateral Sclerosis (ALS) | |
| Phase 1Completed | 22 Oct 2018 | A Phase I Study to Assess the Safety of Pegcetacoplan (APL-2) as an Add-On to Standard of Care in Subjects With PNH | |
| Phase 1Completed | 26 Aug 2019 | Pilot Study to Assess Safety, Preliminary Efficacy and Pharmacokinetics of S.C. Pegcetacoplan (APL-2) in PNH Subjects. | |
| Phase 1Completed | 1 Apr 2021 | Study to Evaluate the Safety of Intravitreal APL-2 in Patients Diagnosed With Geographic Atrophy |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026